SecBot SecBot
SECBOTREPLAY Home › Report › IMTX

IMTX · Immatics announced a deep and durable remission in a pediatric patient…

Immatics N.V. · 6-K filed Apr 17, 2026 at 15:06 ET

At the news

BULLISHIMPACT 8/10

6-K filed Apr 17, 2026 at 15:06 ET

Immatics announced a deep and durable remission in a pediatric patient with advanced metastatic nephroblastoma treated with its PRAME-directed TCR T-cell therapy, marking a significant clinical proof-of-concept for its platform in pediatric solid tumors. The data will be presented at AACR 2026, reinforcing confidence in PRAME as a high-value target.

  • 17-year-old pediatric patient with PRAME-positive advanced nephroblastoma achieved deep remission after treatment with Immatics' PRAME-directed TCR T-cell therapy (IMA203CD8)
  • Patient had bulky, rapidly progressing disease with metastases to liver, lung, and brain and no remaining treatment options
  • Remission was observed at 3 months and ongoing at 6 months post-infusion, with marked regression on PET/MRI and molecular remission via liquid biopsy
  • Safety profile included manageable cytokine release syndrome resolved with standard therapy

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access